Example: Heart Attack

Clinical Trials on Essential Thrombocythemia

Total 262 results

NCT04551053

Not yet recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

Conditions: Myelofibrosis; Primary Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia Vera Myelofibrosis
NCT04551066

Not yet recruiting

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

Conditions: Myelofibrosis; Primary Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia Vera Myelofibrosis
NCT04517851

Not yet recruiting

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Conditions: Myelofibrosis Transformation in Essential Thrombocythemia; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Primary Myelofibrosis
NCT04485260

Not yet recruiting

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Conditions: Myelofibrosis
NCT04455841

Not yet recruiting

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Conditions: Anemia; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosis
NCT04446650

Not yet recruiting

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Conditions: Primary Myelofibrosis
NCT04285086

Recruiting

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Conditions: Essential Thrombocythemia
NCT04283526

Not yet recruiting

Study of Select Combinations in Adults With Myelofibrosis

Conditions: Primary Myelofibrosis; Myelofibrosis; PMF; Post-Essential Thrombocythemia Myelofibrosis; Post-Polycythemia Vera Myelofibrosis
NCT04282187

Recruiting

Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Conditions: Acute Myeloid Leukemia; Essential Thrombocythemia; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Myeloproliferative Neoplasm; Myeloproliferative Neoplasm, Unclassifiable; Polycythemia Vera; Primary Myelofibrosis; Secondary Myelofibrosis
NCT04279847

Not yet recruiting

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis

Conditions: Relapsed or Refractory Primary Myelofibrosis; Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)
NCT04262141

Recruiting

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

Conditions: Essential Thrombocythemia; Polycythemia Vera
NCT04254978

Recruiting

IMG-7289 in Patients With Essential Thrombocythemia

Conditions: Essential Thrombocythemia
NCT04243122

Not yet recruiting

Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients

Conditions: Myeloproliferative Neoplasm; Essential Thrombocythemia; JAK2 Mutation; Polycythemia Vera; Primary Myelofibrosis; Venous Thromboembolism
NCT04226950

Recruiting

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Childhood Essential Thrombocythemia

Conditions: Essential Thrombocytopenia
NCT04218071

Recruiting

Actuate 1901: 9-ING-41 in Myelofibrosis

Conditions: Myelofibrosis
NCT04177576

Recruiting

Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms

Conditions: Myeloproliferative Neoplasm
NCT04173494

Recruiting

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM)

Conditions: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
NCT04081220

Recruiting

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

Conditions: Thrombocythemia, Essential
NCT04054245

Withdrawn

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Conditions: Myelofibrosis Transformation in Essential Thrombocythemia; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Primary Myelofibrosis
NCT04051307

Recruiting

Dual Vaccine Trial in Myeloproliferative Neoplasms

Conditions: Polycythemia Vera; Essential Thrombocythemia
NCT04041050

Recruiting

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Conditions: Myeloproliferative Neoplasm
NCT03972943

Recruiting

CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia

Conditions: CALR Gene Mutation; Essential Thrombocythemia; JAK2 Gene Mutation; MPL Gene Mutation; Obstructive Sleep Apnea Syndrome; Polycythemia Vera
NCT03952039

Recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Conditions: Primary Myelofibrosis; Post-Polycythemia Vera; Myelofibrosis
NCT03935555

Recruiting

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Conditions: Primary Myelofibrosis (PMF); Post-Polycythemia Vera Myelofibrosis (Post-PV MF); Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
NCT03907436

Completed

The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase

Conditions: Myeloproliferative Disorder; Myeloproliferative Syndrome; Myelofibrosis; Polycythemia Vera; Essential Thrombocythemia
NCT03895112

Recruiting

MPN-RC 118 AVID200 in Myelofibrosis

Conditions: Primary Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post ET MF; Post PV MF
NCT03878199

Recruiting

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Conditions: Essential Thrombocythemia; Myelofibrosis; Myeloproliferative Neoplasm; Polycythemia Vera; Secondary Acute Myeloid Leukemia
NCT03869476

Recruiting

Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.

Conditions: Myeloproliferative Disorder; Essential Thrombocythemia; Primary Myelofibrosis, Prefibrotic Stage; Primary Myelofibrosis, Fibrotic Stage
NCT03862157

Recruiting

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Chronic Eosinophilic Leukemia, Not Otherwise Specified; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Dysplasia; Essential Thrombocythemia; FGFR1 Gene Rearrangement; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Myeloid Neoplasm; Myeloproliferative Neoplasm; Myeloproliferative Neoplasm, Unclassifiable; Overt Primary Myelofibrosis; PDGFRA Gene Rearrangement; PDGFRB Gene Rearrangement; Polycythemia Vera; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Prefibrotic/Early Primary Myelofibrosis
NCT03828422

Active, not recruiting

Arterial Function and Atherosclerosis in Essential Thrombocythemia

Conditions: Atherosclerosis
NCT03755518

Recruiting

A Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia

Conditions: Primary Myelofibrosis; Post-Polycythemia Vera; Myelofibrosis
NCT03745378

Completed

Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)

Conditions: Polycythemia Vera; Essential Thrombocythemia; Myelofibrosis
NCT03662126

Recruiting

KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor

Conditions: Primary Myelofibrosis (PMF); Post-Polycythemia Vera MF (Post-PV-MF); Post-Essential Thrombocythemia MF (Post-ET-MF)
NCT03627403

Recruiting

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Conditions: Primary Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosis
NCT03625895

Completed

Agrylin Drug Use-Result Survey

Conditions: Essential Thrombocythemia (ET)
NCT03566446

Active, not recruiting

CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms

Conditions: Myeloproliferative Neoplasm, Unclassifiable; Essential Thrombocythemia; Myelofibrosis
NCT03441113

Enrolling by invitation

Extended Access of Momelotinib in Adults With Myelofibrosis

Conditions: Post-polycythemia Vera Myelofibrosis (Post-PV MF); Primary Myelofibrosis (PMF); Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
NCT03373877

Active, not recruiting

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Conditions: Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
NCT03289910

Recruiting

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Chronic Myelomonocytic Leukemia; Essential Thrombocythemia; Myelodysplastic/Myeloproliferative Neoplasm; Myelofibrosis; Polycythemia Vera; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
NCT03232177

Recruiting

Anagre Cap. in Patients With High-Risk Essential Thrombocythemia

Conditions: Essential Thrombocythemia
NCT03222609

Recruiting

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Conditions: Myelofibrosis (MF)
NCT03212053

Completed

Prospective Study of Different Biological Tests (Multiplate, ROTEM) in a Cohort of Patients Followed for Essential Thrombocytemia (ET)

Conditions: Thrombocythemia Essential
NCT03194542

Recruiting

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Conditions: Primary Myelofibrosis; Anemia
NCT03165734

Recruiting

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Conditions: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
NCT03136185

Recruiting

IMG-7289 in Patients With Myelofibrosis

Conditions: Myelofibrosis; Post-polycythemia Vera Myelofibrosis (PPV-MF); Post-essential Thrombocythemia Myelofibrosis (PET-MF); Primary Myelofibrosis (PMF)
NCT03123588

Active, not recruiting

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Conditions: MPN (Myeloproliferative Neoplasms)
NCT03121599

Terminated

18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms

Conditions: Essential Thrombocythemia; Primary Myelofibrosis, Fibrotic Stage; Primary Myelofibrosis, Prefibrotic Stage; Polycythemia Vera
NCT03116542

Recruiting

18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia

Conditions: Essential Thrombocythemia; Primary Myelofibrosis, Fibrotic Stage; Primary Myelofibrosis, Prefibrotic Stage
NCT03065400

Completed

PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

Conditions: Chronic Phase Myelofibrosis; Primary Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Polycythemia Vera
NCT02966353

Completed

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

Conditions: Primary Myelofibrosis; Post-Polycythemia Vera-Myelofibrosis; Post-Essential Thrombocythemia Myelofibrosis

COOKIE SETTINGS

Clinical Trials on Essential Thrombocythemia